Company Announcements & Press Releases

RhoVac AB’ announcement on company’s Phase I/II study

17 August, 2017

RhoVac AB (“RhoVac”) announced that in January 2017, the company received the respective medicines agency and ethical committee’s approval for the start of the Phase I/II study. The study started immediately and in early April 2017 the first patient was treated. Today, all 22 patients are under treatment. Company’s CEO, Anders Ljungqvist, provides information on the status of the clinical study in this newsletter.

At the beginning of July 2017, RhoVac announced the completion of patients’ recruitment for company’s Phase I/II study in which a total of 22 people were recruited. All patients have now received at least three vaccinations. The patient who has reached the furthest in the treatment has received eight vaccinations. In total, patients should be treated with eleven vaccinations. It is estimated that the last patient will receive the eleventh vaccination in February 2018. Thereafter, immunological analyses will follow and reporting of the trial is expected in Q2 2018.

Patients are evaluated for safety at the clinical department at all twelve visits of the treatment period. The vaccinations are also administrated during these visits. Current status, in mid-August 2017, is that RhoVac is experiencing a high level of commitment from patients who even during their holiday season are visiting the clinical department for the safety evaluations. To date, the company has not encountered any safety issues that impact the continuation of the study. Therefore, RhoVac expects to complete the clinical phase I/II study on scheduled time as planned.

Anders Ljungqvist – VD, RhoVac AB
Phone: +45 4083 2365
E-mail: alj@rhovac.com


About RhoVac AB
RhoVac AB conducts research and development of immunotherapeutic drugs. The company’s main focus is the development of a therapeutic cancer vaccine with the potential to prevent or limit metastasis in cancer. RhoVac’s first drug candidate has completed pre-clinical phase and clinical phase I / II study has started spring 2017. RhoVac has its head office at Medicon Village in Lund, Sweden. The research has been conducted since 2007 primarily at the University Hospital in Herlev, Denmark, by a world-class research team in its niche. RhoVac is listed on AktieTorget, Sweden, a Multilateral Trading Facility (MTF), since March 2016 and has approximately 1,700 shareholders. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com